Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia

Abstract

The use of ADT is associated with an increased risk of hospitalisation for community-acquired pneumonia in men with prostate cancer.

Can network pharmacology identify the anti-virus and anti- inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection?

“…By regulating cellar proliferation or survival, AR negatively regulates the number of alveolar macrophages (AM) to reduce the recruitment of inflammatory factors in the lung [63]. Given the AR receptor knocked out, the human body would be more susceptible to microbial, thus the risk of hospitalization for pneumonia would increase [64]. In addition, these major hub genes all had great binding capacity to the key compounds by molecular docking verification.…”

Impact of 23‐valent pneumococcal polysaccharide vaccination on the frequency of pneumonia‐related hospitalization and survival in elderly patients with prostate cancer: A seven‐year nationwide matched cohort study

“…ADT is an important treatment modality for patients with prostate cancer, and several studies have demonstrated an increased risk of pneumonia in patients with prostate cancer who receive gonadotropin-releasing hormone. [15][16][17] A population-based cohort study using data from the UK Clinical Practice Research Datalink linked to the Hospital Episode Statistics repository assessed 20,310 men newly diagnosed with nonmetastatic prostate cancer and demonstrated that current ADT treatment was associated with a higher risk of hospitalization for community-acquired pneumonia. 17 Several Figure 3.…”

“…[15][16][17] A population-based cohort study using data from the UK Clinical Practice Research Datalink linked to the Hospital Episode Statistics repository assessed 20,310 men newly diagnosed with nonmetastatic prostate cancer and demonstrated that current ADT treatment was associated with a higher risk of hospitalization for community-acquired pneumonia. 17 Several Figure 3. Kaplan-Meier survival curves are illustrated for elderly patients with prostate cancer who did and did not receive the 23-valent pneumococcal polysaccharide vaccine (PPSV23) (log-rank test; P = .0003).…”

“…13 Androgen receptors are expressed on several immunologic cells and play an important role in immune system regulation, 14 and previous studies have demonstrated that ADT is associated with an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in patients with prostate cancer. [15][16][17] Among pneumonia-causing pathogens, Streptococcus pneumoniae is prevalent in approximately 60% of infections and remains a major cause of morbidity and mortality worldwide. 18,19 The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is effective for preventing pneumococcal infections in 65% to 84% of patients with diabetes mellitus (DM), chronic pulmonary diseases, or congestive heart failure (CHF).…”

Thinking outside the lungs: ‘other’ risk factors for pneumonia hospitalisation

“…In Thorax , Hicks et al 9 carried out a large-scale, population-based study of UK men with newly diagnosed non-metastatic prostate cancer between 1998 and 2015. They used data obtained from electronic healthcare records to comprehensively measure the risk of hospitalisation for CAP, comparing patients currently being treated with ADT, or patients who had past ADT use, to patients who had never received ADT.…”